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Abstract 23 
Aims: to evaluate the effects of antihypertensive drug classes in mortality in patients with 24 
type 2 diabetes. 25 
Methods: MEDLINE, EMBASE, Clinical Trials and Cochrane Library were searched for 26 
randomized trials comparing thiazides, beta-blockers, calcium channel blockers (CCBs), 27 
angiotensin-converting inhibitors (ACEi) and angiotensin-receptor blockers (ARBs ), alone 28 
or in combination for hypertension treatment in patients with type 2 diabetes. Outcomes were 29 
overall and cardiovascular mortality. Network Meta-Analysis was used to obtain pooled 30 
effect estimate.  31 
Results: 27 studies, comprising 49418 participants, 5647 total and 1306 cardiovascular 32 
deaths were included. No differences in total or cardiovascular mortality were observed with 33 
isolated antihypertensive drug classes compared to each other or placebo. ACEi and CCB 34 
combination showed evidence of reduction in cardiovascular mortality comparing to placebo 35 
(median HR, 95% Credibility Intervals: 0·16, 0·01-0·82), betablockers (0·20, 0·02-0·98), 36 
CCBs (0·21, 0·02-0·97) and ARBs (0·18, 0·02-0·91). In included trials, this combination was 37 
the treatment that most consistently achieved both lower systolic and diastolic end of study 38 
blood pressure.  39 
Conclusions: There is no benefit of a single antihypertensive class in reduction of mortality 40 
in hypertensive patients with type 2 diabetes. Reduction of cardiovascular mortality observed 41 
in patients treated with ACEi and CCB combination may be related to lower blood pressure 42 
levels. 43 
Key words: Type 2 diabetes, Hypertension, antihypertensive drugs, mortality 44 
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1. INTRODUCTION 45 
Association between hypertension and diabetes mellitus (DM) is common. There is a 2.5 times higher 46 
risk of DM among hypertensive patients and hypertension affects up to 70% of patients with type 2 47 
DM [1,2]. Hypertension increases 7.2 times the risk of death in patients with DM, especially due to 48 
cardiovascular disease [3].
 
 49 
Treatment of hypertension in patients with type 2 DM diminishes the risk of micro- and 50 
macrovascular outcomes. In United Kingdom Prospective Diabetes Study (UKPDS), intensive control 51 
of hypertension reduced diabetes related deaths, stroke, and microvascular complications, especially 52 
diabetic retinopathy [4]. 53 
There is still debate about which would be the most favorable antihypertensive class in patients with 54 
type 2 DM. Current guidelines usually recommend that drugs blocking the renin-angiotensin-55 
aldosterone system are preferred agents in the treatment of diabetic patients due to their potential 56 
beneficial effects besides reduction of blood pressure [5].
 
However, their actual effect on mortality is 57 
controversial. Some systematic reviews and traditional meta-analyses have been performed to 58 
evaluate the efficacy of antihypertensive drug classes in mortality and cardiovascular events in 59 
patients with and without diabetes. However, Network Meta-analysis (NMA), also known as mixed 60 
treatment comparisons (MTC), method is not commonly used, therefore limiting interpretation of the 61 
results [6,7].
 
NMA are an extension of meta-analysis to compare more than two treatments and are 62 
essential to make coherent decisions when multiple treatments are available [8]. They allow the 63 
comparison of treatments that have not been directly compared in head-to-head trials, thereby making 64 
it possible to rank all the treatments, and to pool all the available evidence [9].
 
One NMA concluded 65 
that is no or just little difference between commonly used blood pressure lowering agents in the 66 
prevention of cardiovascular disease in the general hypertensive population [10]. Recently, a NMA 67 
compared the effectiveness of antihypertensive drugs in patients with diabetes [11] and authors 68 
concluded that only ACE inhibitors had a renoprotective effect, but no statistically significant 69 
difference in total mortality was observed. However, the authors included patients with both type 1 70 
and type 2 diabetes, and patients without established hypertension, which may have influenced the 71 
results.  We believe it is more clinically relevant to analyze the efficacy of antihypertensive agents on 72 
hard outcomes – total mortality and cardiovascular mortality – in a more homogeneous and prevalent 73 
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population of patients with type 2 diabetes and hypertension. Therefore, the aim of this study is to 74 
analyze the effects of each of the main antihypertensive drug classes used alone or in combination in 75 
hypertensive patients with type 2 DM on total and cardiovascular (CV) mortality by using NMA. 76 
 77 
2. MATERIALS AND METHODS 78 
The protocol for this network meta-analysis is registered in International prospective register of 79 
systematic reviews (PROSPERO) and available from www.crd.york.ac.uk/NIHR_PROSPERO with 80 
registration number CRD42012001702. 81 
2.1 Data Sources and Search 82 
We searched MEDLINE, EMBASE, Clinical Trials and Cochrane Library from 1950 to November, 83 
2012 using the Medical Subject Heading terms type 2 diabetes and hypertension or each drug by 84 
name of the defined antihypertensive classes defined (thiazide diuretics, betablockers, calcium 85 
channel blockers (CCBs), angiotensin converting enzyme inhibitors (ACEi), and angiotensin receptor 86 
blockers (ARBs)) and a validated filter
 
to identify randomized clinical trials [12], reporting 87 
cardiovascular events or death (detailed search strategy is described in supplemental material). We 88 
searched also abstracts from major cardiology, nephrology and endocrinology meetings. A manual 89 
search was also performed through references of reviews, previous meta-analysis and key articles. All 90 
potential eligible trials were considered for review regardless of the primary outcome or language. 91 
2.2. Study selection 92 
Trials were considered for inclusion if they were conducted in hypertensive adults older than 18 years 93 
with type 2 DM, compared the effects of one of the classes, or combinations of classes, of 94 
antihypertensive agents with another or placebo, had at least 12 months of follow up and reported 95 
incidence of cardiovascular or total mortality. Studies not designed for the treatment of hypertension 96 
were eligible if more than 95% of patients included had hypertension. The definitions of hypertension 97 
were the ones defined in each study based on contemporary recommendations when studies were 98 
planned.  Two independent investigators (LRR and LPK) selected potentially eligible studies based on 99 
titles and abstracts and these were retrieved for full-text evaluation. Disagreements were resolved by a 100 
third investigator (CBL). 101 
2.3. Data Extraction, and Quality Assessment 102 
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Studies that met inclusion criteria were included and two investigators extracted information on: study 103 
design,  intervention and control group, number of participants, trial duration, drug class and dose of 104 
the antihypertensive agent used, age, sex distribution, cardiovascular risk factors such as total, HDL 105 
and LDL cholesterol, creatinine, HbA1c, baseline arterial blood pressure (BP), smoking habit and 106 
urinary albumin excretion rate  as well as outcome data for myocardial infarction, stroke and death. 107 
Any discrepancies between data extracted were discussed and a consensus was reached. Whenever 108 
necessary, authors were contacted in order to obtain additional needed data. Quality of trials and risk 109 
of bias were assessed using recommendations from Preferred Reporting Items for Systematic reviews 110 
and Meta-Analyses (PRISMA) and quality of the evidence was assessed using Grading of 111 
Recommendations Assessment, Development and Evaluation (GRADE) system [13-15]. 112 
2.4. Data Synthesis and Analysis 113 
Analyzed outcomes were mortality from all causes and cardiovascular mortality defined as death due 114 
to fatal cardiac events or stroke were recorded.  115 
Data from all the publications were entered into a computerized spreadsheet (Microsoft Excel) and 116 
NMA models were estimated using Bayesian Markov Chain Monte Carlo simulation implemented in 117 
the freely available Bayesian software WinBUGS (Medical Research Council Biostatistics Unit, 118 
Cambridge, United Kingdom; www.mrc-bsu.cam.ac.uk/bugs). WinBUGS model used is available on 119 
Supplemental Material. For the mortality outcomes we modeled the log-hazard ratio of events over 120 
time, assuming proportional hazards, and report posterior median Hazard Ratios (HR) with 95% 121 
credible intervals (95% CrIs) that are the Bayesian equivalent to confidence intervals . For the blood 122 
pressure outcomes we modeled the mean differences in blood pressure at the follow-up time [8, 16], 123 
and report posterior median differences with 95% CrIs. The specific code and data structure used are 124 
available from the authors on request. We also assessed the probability that each antihypertensive 125 
class is ranked as the 1
st 
best, 2
nd
 best, 3
rd
 best through to worst treatment in reducing cardiovascular 126 
and total mortality using placebo as the reference treatment.  127 
We assessed model fit of fixed and random effects models using the posterior mean of the residual 128 
deviance [8, 16]. ].
 
Statistical heterogeneity of the NMA was evaluated comparing the deviance 129 
information criteria (DIC) between fixed and random effect models (see Supplemental Material for 130 
details). 
 
We decided to use the more conservative random effects (RE) model since there was an a 131 
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priori expectation that there would be heterogeneity in the evidence as different treatments were 132 
combined into single classes.  NMA assumes that the network is consistent [8]. Consistency was 133 
assessed using the node-split method, where results based on direct and indirect evidence for all pairs 134 
of treatments are compared [17].
 
When a significant inconsistency was found (p<0.05), the first step 135 
was to search for clinical differences in the included trials that may explain the inconsistency and 136 
exclusion of any trials if there is a clinical rationale to do so [18,19]. If we did not find any important 137 
clinical aspect that could justify exclusion of the trial, then a cross-validation analysis was performed. 138 
This analysis predicts the expected number of events (mortalities) in a trial with the same number of 139 
patients and number of control events, as the original trial under consideration, given the evidence 140 
(direct and indirect, when available) from the remaining network. This result is then compared to the 141 
original finding of the trial giving a p-value that is interpreted as the probability of observing such a 142 
result in a trial given all the other evidence. With this analysis it is possible to evaluate if the observed 143 
outcomes in the original trial could be predicted from the variability in the other trials (p-value not 144 
significant), or if the trial was an outlier (p-value significant) [20, 21].  145 
 146 
3. RESULTS 147 
The search retrieved 10692 studies and 10459 were excluded based on title and abstracts. Of the 233 148 
reports assessed for full text analysis, five could not be translated and were excluded, and 30 fulfilled 149 
the inclusion criteria (Figure 1). For three studies, outcomes were described in two different 150 
publications, so there were 27 different trials included [22-51).  151 
3.1. Studies characteristics 152 
Details of the included trials are described in Table 1. The included studies compared 9 types of 153 
antihypertensive treatments (Figure S1). There were 3 trials [30, 33, 40] that compared an active 154 
treatment to conventional treatment that could be a diuretic and/or a betablocker at physician 155 
discretion. These groups were included as a separate class coded as diuretic and/or betablocker. Six 156 
trials included at least one arm that was randomized to a combination of two drugs of different 157 
classes. These arms were coded as different categories of treatments and analyzed in separate as a 158 
treatment strategy comparing then with the other drug and combination classes.  159 
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Risk of bias in the trials is described in Table S1 in supplemental material. All studies were 160 
randomized, however in ten we could not define the method used for randomization and, therefore, its 161 
concealment. Eleven trials were not double blinded; however in all but 2 trials the outcome evaluators 162 
were blinded. . From the 21 studies included in cardiovascular mortality analysis, 16 had all events 163 
adjudicated by an independent committee.  The other 5 trials do not describe if outcomes were 164 
adjudicated and, in 3 of these, the events of death were described in adverse event section. In 9 trials, 165 
the study describes clearly a standardized method for blood pressure measurement. Six trials describes 166 
that clinical assessments including blood pressure were conducted according to the study protocol. 167 
Only in one case, there is no information regarding blood pressure measurement technique. According 168 
to GRADE system, the quality of the evidence was considered moderate (Supplemental Table S2). 169 
Model fit evaluation is detailed in Table S3 in supplemental material. 170 
3.2. Overall mortality 171 
Overall mortality was reported in 25 trials (27 publications) comprising 48171 patients with 5647 172 
deaths and comparing 9 different treatments. Results of RE NMA analysis did not show evidence of 173 
difference between classes of antihypertensives regarding total mortality in comparison to placebo 174 
(Figure 2A). The posterior median of overall heterogeneity was 0.12 (95% CI 0.007 to 0.30). A 175 
borderline effect in reduction of total mortality was observed with the combinations of ACEi plus 176 
CCB and ACEi plus thiazide compared to placebo or to treatment with diuretic and/or betablocker 177 
(Table 2). There was evidence of inconsistency in this model related to comparison of treatment with 178 
betablocker vs ARB. The only trial comparing these treatments was LIFE (Losartan Intervention For 179 
Endpoint Reduction) study. No clinical reasons were identified that set this trial apart from the others 180 
so a predictive cross-validation was carried out, under a RE model. According to this analysis, the 181 
number of events predicted for patients on ARBs treatment would be 111 (95% CrI 75 to 159) and the 182 
observed number of events was 63 (p = 0.0056), suggesting that LIFE was an outlier for this outcome. 183 
The analysis was performed excluding the LIFE trial and results are similar except that there was an 184 
evidence of effect of the combinations of ACEi plus CCB and ACEi plus thiazide compared to 185 
placebo in reduction of mortality (median HR, 95% CrI: 0.324, 0.086 – 0.986 and 0.32, 0.082 – 0.998, 186 
respectively). 187 
3.3. Cardiovascular mortality 188 
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Cardiovascular mortality was described in 21 trials (24 publications) comprising 32101 patients with 189 
1306 deaths due to cardiovascular events and comparing 9 treatments. Results of the RE NMA 190 
analysis showed that the combination of ACEi plus CCB had a lower CV mortality in comparison to 191 
placebo (median HR, 95% CrI: 0.16, 0.01 to 0.82), betablocker (0.20, 0.024 to 0.98), CCB alone 192 
(0.21, 0.02 to 0.97), ARB (0.18, 0.02 to 0.91) and treatment with diuretic and/or betablocker (0.18, 193 
0.02 to 0.91) (Figure 2B and Table 2). The posterior median of overall heterogeneity was 0.39 (95% 194 
CI 0.11 to 0.83). All the other classes had similar CV mortality when compared to each other (Table 195 
2). In this model, there was evidence of inconsistency related to comparison of treatment with placebo 196 
vs. ARB. The only trial that directly compared these treatments was ORIENT (Olmesartan Reducing 197 
Incidence of Endstage renal disease in diabetic Nephropathy Trial). In this trial, unexpectedly, the 198 
number of cardiovascular deaths was higher in the active treatment than in placebo (10/282 vs. 3/284). 199 
A predictive cross-validation analysis was carried out which predicted 6 events in patients treated 200 
with ARBs (95% CrI 0 to 9) while the observed number of events in the ORIENT trial was 10 (p = 201 
0.01). This suggests that this trial is an outlier for this outcome, given the remaining trials and an 202 
analysis was also performed excluding it. In this analysis, the combination of ACEi plus CCB was 203 
also the only treatment with evidence of benefit in reduction of CV mortality, but this effects was 204 
observed only when compared to placebo (0.14, 0.01 to 0.70), CCB alone (0.21, 0.02 to 0.97) and 205 
treatment with diuretic and/or betablocker (0.18, 0.002 to 0.91).  206 
3.4. Ranking of efficacy in reduction of mortality 207 
The distribution of probabilities of each treatment being ranked at each of the possible 9 positions for 208 
the model including all trials is shown in Supplemental Figure S2. Combinations of ACEi plus CCB 209 
and ACE plus diuretic were the most efficacious treatments being more frequently ranked as first or 210 
second best treatments in reducing both total and cardiovascular mortality. Cumulative frequency of 211 
being ranked into the three most efficacious treatments in reducing total mortality were: ACEi plus 212 
CCB 95.9%, ACEi plus diuretic 95.1%, ARB 47.5%, ACEi 23.7%, thiazides 10.5%, betablockers 213 
8.7% and CCBs 7.9%. Cumulative frequency of being ranked into the three most efficacious 214 
treatments in reducing cardiovascular mortality were: ACEi plus CCB 97.1%, ACEi plus diuretic 215 
91.1%, ACEi 30.2%, thiazides 27.8%, betablockers 14.4%, CCBs 11.3%, ARB 9.7%,. 216 
3.5. End-of-study blood pressure  217 
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Considering that the benefit associates with an individual antihypertensive agent could be solely due 218 
to its effect on BP reduction, we also analyzed the effects of each antihypertensive drug class in the 219 
end of study blood pressure for the trials included in the analysis of total and cardiovascular mortality. 220 
We were able to extract data about final systolic and diastolic blood pressure in diabetic patients in 16 221 
of these studies comparing 7 classes of treatment (classes not included due to lack of data were: 222 
diuretic and/or betablocker and ACEi plus diuretic). Results of NMA analysis showed that, compared 223 
to placebo, the combination of ACEi plus CCB had lower final systolic and diastolic blood pressure 224 
levels (median difference, 95% CrI: -4.97, -8.60 to -1.50 and -3.50, -5.62 to -1.41, respectively) as 225 
well as ARB (-3.34, -5.96 to -0.73 and -1.56, -3.09 to -0.04, respectively) (Supplemental Figure S3). 226 
Compared to other active treatments, combination of ACEi and CCB had lower end of trial systolic 227 
and diastolic blood pressure in comparison to ACEi (-3.97, -6.77 to -1.27 and -2.67, -4.31 to -1.03 228 
mmHg, respectively). In addition, ACEi in combination with CCB had lower diastolic blood pressure 229 
levels in comparison to thiazide and CCBs (-2.43, -4.66 to -0.21 and -1.87, -3.58 to -0.17, 230 
respectively) (Table 3).  231 
The probability of each class being ranked as the 1
st 
best, 2
nd
 best, 3
rd
 best through to the least 232 
effective treatment in reducing end of study blood pressure levels is shown in Supplemental Figure 233 
S4. 234 
 235 
4. DISCUSSION 236 
In the present meta-analysis on hypertensive patients with type 2 DM, we did not observe benefits in 237 
reduction on total and CV mortality of any class of a single antihypertensive in comparison to placebo 238 
or other classes. Combination of ACEi plus CCB had lower CV mortality in comparison to other 239 
classes, and this was also the treatment that most consistently achieved both lower systolic and 240 
diastolic end of study blood pressure. 241 
The results presented here are in accordance with findings from UKPDS which showed a significant 242 
reduction of 12% in total mortality with a 10 mmHg reduction in blood pressure but did not find 243 
differences in treatments with captopril or atenolol, suggesting that blood pressure reduction is more 244 
important than the selection of a specific drug class [4, 22, 52]. Thus, the benefit on CV mortality 245 
observed with combination of ACEi plus CCB may be related to lower blood pressure values 246 
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achieved by this strategy. However, we have to take into account that this analysis was conducted 247 
only in the trials that were included in the mortality analysis, therefore it is not a comprehensive NMA 248 
of the antihypertensive effect of these classes.  249 
Other meta-analyses have evaluated the effects of antihypertensive treatment in the prevention of 250 
cardiovascular events. A previous NMA found small or no differences among antihypertensive drug 251 
classes in hypertensive patients [10]. A direct meta-analysis comparing antihypertensive treatment in 252 
diabetic patients did not show differences between ACEi and CCB or any of these classes and 253 
conventional treatment with diuretic or betablocker in mortality, and, besides, this study did not 254 
include analysis of the efficacy of ARBs and diuretics or betablockers separately [7]. In a previous 255 
published NMA [11], ACE inhibitors were considered superior to the other agents in patients with 256 
diabetes only regarding the outcome of doubling serum creatinine, and there was no significant effect 257 
on total mortality. In our study we observed an evidence of effect on cardiovascular mortality of the 258 
combination ACEi + CCB, and in treatment ranking this combination has the highest probability to be 259 
the most effective treatment for reduction both total and cardiovascular mortality. Althoug the HR 260 
estimate for this treatment is quite low, it is important to note that credible intervals are wide. 261 
Probably we were able to observe this effect because we included only type 2 diabetic patients with 262 
hypertension, who have a well-known risk for cardiovascular mortality [2]. Moreover, the reduction 263 
in blood pressure was more evident with the combination ACEi + CCB.    264 
The strength of the meta-analysis presented here is the number of included patients and events and the 265 
fact that we analyzed mortality outcomes only and not surrogate endpoints. Another advantage of this 266 
study is the use of a NMA method to evaluate the effects of the different antihypertensive drug classes 267 
relative to each other in a coherent way.  This analysis has limitations. NMA method takes into 268 
account several statistical assumptions that can not be verified and could introduce bias. However, 269 
bias is not expected to act exclusively in one particular direction and NMA method is considered 270 
essential to make comparisons when multiple treatments are available [53]. Like in other multiple 271 
comparisons, these conclusions must be interpreted with caution and proper clinical judgment. For 272 
several trials, we had no details of baseline characteristics of patients, in order to estimate a baseline 273 
cardiovascular risk to use in the analysis as a correction factor. In addition, data about initial and/or 274 
final blood pressure was not available for some of the trials, precluding its inclusion as a covariate in a 275 
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metaregression and allowing only the evaluation of the effect of  antihypertensive drug classes on 276 
blood pressure as a separate analysis. These two factors would be particularly important in the 277 
analysis in order to correct for potential confounding factors between studies.  The different treatment 278 
and even placebo arms  may have received additional drugs as rescue therapy during the trials and this 279 
fact could explain the lack of difference in end of trial blood pressure of most antihypertensive drug 280 
classes compared to placebo in the network analysis. This  is an important potential confounding 281 
factor in meta-analysis of these trials as it could minimize the effects of each randomized drug class 282 
that was being evaluated in individual trials. We included three trials that used diuretic or betablocker 283 
at the discretion of the physician and outcomes for these patients were grouped as described by 284 
Fretheim et al [10]. As this is not one drug class nor exactly a combination, the results of these 285 
comparisons were not considered clinically significant.  Moreover, we included data from subgroup of 286 
patients with diabetes of larger trials that included non diabetic patients in the original randomized 287 
sample and studies were health care providers and/or patients were not blinded.  288 
There was also some evidence of conflict between direct and indirect evidence in our models and 289 
there is controversy about what is the best strategy to deal with it [18,19]. In the analysis of overall 290 
mortality, the LIFE study was considered an outlier due to a higher than predicted number of deaths in 291 
atenolol group. Regarding cardiovascular mortality, the same unexpected result was found in 292 
olmesartan group in the ORIENT trial and there was also evidence to suggest that this trial may be an 293 
outlier, given the remaining evidence. Other studies had also suggested a worse outcomes with use of 294 
olmesartan [54, 55]. Nevertheless, the results in this meta-analysis did not change in essence if the 295 
LIFE and ORIENT trials are not included in the total and cardiovascular mortality analyses, 296 
respectively.   297 
In conclusion, our results did not demonstrate a benefit of one class of a single antihypertensive over 298 
another in reduction of mortality in patients with type 2 diabetes and hypertension. A combination of 299 
drugs, ACEi plus CCB, appeared more effective in reducing CV mortality. We hypothesise that 300 
maybe the benefits of this drug combination may be mediated by its apparent better efficacy in blood 301 
pressure reduction rather than an effect of the specific antihypertensive agents.  302 
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Table 1: Details of the included trials.   
Author Study Year Follow 
up 
(years) 
Mean 
age 
(years) 
DM 
duration 
(years) 
Lost to 
follow up 
(%) 
Study/drug 
discon-
tinuation 
(%) 
§
 
Groups Mean 
Initial BP -  
mmHg  
(SD) 
Mean Final 
BP - 
mmHg 
(SD) 
Total 
deaths 
(events/n) 
CV deaths 
(events/n) 
Bakris INVEST 
(DM subgroup) 
2004 5 66  
- 
 2.52 * 9.28 * Verapamil SR 151.1/85.5 
(19.6/12.2) 
 
- 
370/3169 190/3169 
        Atenolol 150.5/85.4 
(19.8/12.1) 
 355/3231 161/3231 
Barnett DETAIL 2004 5 60.57 8 0.71 28.57 Telmisartan 152.6/85.4 
(16.6/8.8) 
 
- 
6/120 3/120 
        Enalapril 151.6/85.9 
(15.8/7.8) 
 6/130 2/130 
Berl and  IDNT 2003 4.5 58.9  0.64 24.55 Ibesartan 160/87 
(20/11) 
140/77 (-/-) 87/579 52/579 
Lewis     -   Amlodipine 159/87 
(19/11) 
141/77 (-/-) 83/567 37/567 
        Placebo 158/87 
(20/11) 
144/80 (-/-) 93/569 46/569 
Brenner RENAAL 2001 4 60   29.28 Losartan 152/82 
(19/10) 
140/74 (-/-) 158/751  
- 
     - -  Placebo 153/82 
(20/11) 
142/74 (-/-) 155/762  
Curb SHEP 
(DM subgroup) 
1996 5 70.35  
- 
 
- 
 
- 
Chlorthalidone 170.2/76.9 
(9.2/8.9) 
 
- 
39/283  
- 
        Placebo 170.2/74.8 
(9.2/10) 
 48/300  
Estacio ABCD 1998 5 57.45 8.6  
- 
52.55 Nisoldipine 155/98 
(19/7) 
 
- 
18/235 11/235 
        Enalapril 156/98 
(17/7) 
 14/235 6/235 
Fogari  2002 4 62.52 8.76  
 
4.74 Amlodipine 160.4/99.3 
(14.4/7.1) 
140.4/86.5 
(10.1/5.4) 
4/103 2/103 
      -  Fosinopril 159.5/99.1 
(13.3/6.7) 
142.3/87.3 
(10.4/5.6) 
3/102 2/102 
        Amlodipine + 
fosinopril 
161.1/99.4 
(16.2/6.6) 
132.4/82.3 
(9.9/5.1) 
2/104 1/104 
Hansson NORDIL 2000 5   0.48 * 14.93 * Diltiazem   28/351 15/351 
    - -   Diuretic and/or 
betablocker 
- - 26/376 13/376 
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Imai ORIENT 2011 4.5 59.15  
- 
 
- 
24.2 Olmesartan 141.7/77.8 
(17/10.4) 
131.8/72.2 
(-/-) 
19/282 10/282 
        Placebo 140.8/77.2 
(18/10.6) 
136.6/73.6 
(-/-) 
20/284 3/284 
Lindholm LIFE 2002 5.5 67.4  
- 
0.33 5.36 Losartan 176/97 
(14/9) 
146/79 
(17/11) 
63/586 38/586 
 (DM subgroup)       Atenolol 177/96 
(14/10) 
148/79 
(19/11) 
104/609 61/609 
Lindholm STOP-2 
(DM subgroup) 
2000 2 75.8  
 
  Diuretics and/or 
Betablocker 
195/97 
(-/-) 
161.3/81.2 
(-/-) 
67/253 45/253 
     - - - Calcium antagonist 196/97 
(-/-) 
161.8/79.1 
(-/-) 
50/231 33/231 
        ACEi 196/96 
(-/-) 
161.8/80.3 
(-/-) 
56/235 39/235 
Mancia INSIGHT 
(DM subgroup) 
1993 4 65.54  
- 
2.36 * 34.14 * Nifedipine 174.7/98.2 
(15.8/9.2) 
161.3/81.9 
(16.1/9.4) 
44/649 19/649 
        Hydrochlorothiazide 
+ amiloride 
175.7/9737 
(15.1/9.1) 
143.6/82.4 
(17/9.7) 
59/653 19/653 
Marre  NESTOR 2004 1 59.98 8.23  
- 
11.25 Indapamide 161.1/94 
(10.8/6.9) 
137.3/81 
(12/8.1) 
2/284 2/284 
        Enalapril 160.2/93.5 
(10.8/6.1) 
139.3/81.4 
(14.3/7.9) 
1/286 1/286 
Muramatsu NAGOYA 
HEART 
2012 4.5 63  
- 
2.61  
- 
Valsartan 145/82 
(18/13) 
131/73 
(-/-) 
22/575  
- 
        Amlodipine 144/81 
(19/13) 
132/74 
(-/-) 
16/575  
Nakao CASE-J 
(DM subgroup) 
2010 4 64  
- 
2.89 * 8.46 * Candesartan 159.8/88.3 
(12.9/9.9) 
 
- 
40/1011 11/1011 
        Amlodipine 160/88.3 
(12.5/10.3) 
 49/1007 15/1007 
Nielsen  1997 3.5  
- 
 
- 
 
- 
25.0 Lisinopril 172/87 
(22.9/13.7) 
163/82 
(22.9/9.1) 
 
- 
1/21 
        Atenolol 174/94 
(23.5/11.7) 
166/84 
(23.5/11.7) 
 3/22 
Niskanen CAPPP 
(DM subgroup) 
2001 5.5 55.32  
- 
0.17  
- 
Captopril 163.6/97.1 
(18.8/9.6) 
 
- 
20/309 9/309 
        Diuretic and/or 
betablocker 
163.3/97.3 
(20.6/10.1) 
 34/263 15/263 
Ostergren ASCOT 
(DM subgroup) 
2008 5 63.4  
- 
0.25  
- 
Amlodipine 164.9/92.7 
(18.2/10.4) 
136/75 
(-/-) 
245/2565 94/2565 
        Atenolol 164.8/92.3 
(17.9/10.3) 
137/76 
(-/-) 
250/2572 96/2572 
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Parving IRMA 2001 2 58 9.7 0.51 11.86 Ibesartan 153/90 
(14/9) 
 
- 
3/389  
- 
        Placebo 153/91 
(15/10) 
 1/201  
Remuzzi BENEDICT-A 2006 4 62.34 7.85 1.33 48.17 Trandolapril + 
Verapamil 
150.5/87.3 
(13.3/8.1) 
139/80 
(10/6) 
 
 
0/300 
        Trandolapril 150.8/87.4 
(14.8/7.7) 
139/81 
(12/6) 
 
- 
1/301 
        Verapamil 150.1/87.5 
(13.1/7.2) 
141/82  
(10/6) 
 1/303 
        Placebo 151.9/87.7 
(15.4/7.6) 
142/83  
(12/6) 
 3/300 
Ruggenenti BENEDICT-B 2011 4 62.35 9.25 3.20 47.33 Verapamil + 
Trandolapril 
150.1/86.5 
(16/9.5) 
141/81.6 
(11.5/6.4) 
2/138 1/138 
        Trandolapril 148.9/86.2 
(16.7/9) 
141.8/82.3 
(12.2/6.7) 
7/143 4/143 
Safar and 
Tuomilehto 
SYST-EUR 
(DM subgroup) 
2003 5  
- 
 
- 
5.05 *  
- 
Nitrendipine  
- 
 
- 
19/278 5/278 
        Placebo   27/269 16/269 
Tatti FACET 1998 4 63.05 10.59 1.05 23.16 Fosinopril 170/95 (-/-) 157/88 (-/-) 4/189  
        Amlodipine 171/94 (-/-) 153/86 (-/-) 5/191  
Weber M ACCOMPLISH 
(DM subgroup) 
2010 3.5 67.5  
- 
1.02 * 30.0 * Benazepril + 
amlodipine 
 
- 
131.5/72.6  
(-/-) 
141/3478 62/3478 
        Benazepril + 
hydrochlorothiazide 
 132.7/73.7  
(-/-) 
139/3468 74/3468 
Whelton ALLHAT 
(DM subgroup) 
2005 6 66.6  
 
3.08  Chlortalidone 146.4/83.9 
(15.5/9.9) 
135/74.4 
(15.6/9.7) 
1145/5994  
     -  - Amlodipine 146.4/82.7 
(15.6/10.1) 
136.3/73.6 
(15.9/10.1) 
683/3597 - 
        Lisinopril 146.9/83.1 
(15.5/9.9) 
137.9/74.6 
(19/11.1) 
674/3510  
Yui Y JMIC-B 
(DM subgroup) 
2004 3 64.26  
- 
6.06 * 15.15 * Nifedipine retard 147/82 
(18/12) 
138/76 
(14/8) 
2/199 1/199 
        Imidapril or 
Lisinopril 
146/81 
(20/11) 
140/78 
(16/9) 
5/173 3/173 
 UKPDS 39 1998 9 56.15 2.64  
- 
 
- 
Captopril 159/94 
(20/10) 
144/83 
(14/8) 
75/400 48/400 
        Atenolol 159/93 
(19/10) 
143/81 
(14/7) 
59/358 32/358 
DM = Diabetes Mellitus; BP = blood pressure; CV = cardiovascular
 507 
§
excluding deaths 508 
23 
 
* data from the whole original sample and not only DM subgroup 509 
(-) data not available510 
24 
 
Table 2: Comparisons of the effects of antihypertensive drug classes in total and cardiovascular (CV) 511 
mortality (median Hazard Ratio (95% CrI)).  512 
 513 
Placebo 0.85 
(0.24 – 2.79) 
0.81 
(0.35 – 1.74) 
0.78 
(0.37 – 1.44) 
0.72 
(0.29 – 1.51) 
0.89 
(0.45 – 1.79) 
0.90 
(0.33 – 2.14) 
0.16 
(0.01 – 0.82) 
0.19 
(0.01 – 1.28) 
0.98 
(0.72 – 1.32) 
Thiazide 0.94 
(0.30 – 2.95) 
0.91 
(0.32 – 2.48) 
0.85 
(0.26 – 2.43 
1.04 
(0,.33 – 3.47) 
1.06 
(0.30 – 3.4) 
0.19 
(0.02 – 1.18) 
0.23 
(0.01 – 1.79) 
0.98 
(0.72 – 1.31) 
1.0 
(0.74 – 1.34) 
BB 0.97 
(0.55 – 1.58) 
0.89 
(0.45 – 1.56) 
1.10 
(0.58 – 2.21) 
1.12 
(0.48 – 2.38) 
0.20 
(0.02 – 0.98) 
0.24 
(0.02 – 1.53) 
0.95 
(0.72 – 1.20) 
0.97 
(0.75 – 1.20) 
0.97 
(0.78 – 1.17) 
CCB 0.93 
(0.53 – 1.51) 
1.14 
(0.67 – 2.20) 
1.16 
(0.59 – 2.22) 
0.21 
(0.02 – 0.97) 
0.25 
(0.02 – 1.54) 
0.93 
(0.66 – 1.23) 
0.95 
(0.70 – 1.20) 
0.95 
(0.71 – 1.20) 
0.97 
(0.79 – 1.18) 
ACEi 1.23 
(0.64 – 2.78) 
1.24 
(0.65 – 2.48) 
0.23 
(0.02 – 1.03) 
0.27 
(0.028 – 1.65) 
0.89 
(0.70 – 1.11) 
0.90 
(0.67 – 1.22) 
0.90 
(0.69 – 1.18) 
0.93 
(0.75 – 1.18) 
0.95 
(0.73 – 1.30) 
ARB 1.02 
(0.39 – 2.25) 
0.18 
(0.02 – 0.91) 
0.21 
(0.02 – 1.41) 
1.18 
(0.78 – 1.72) 
1.20 
(0.81 – 1.71) 
1.20 
(0.82 – 1.70) 
1.24 
(0.90 – 1.69) 
1.26 
(0.93 – 1.74) 
1.32 
(0.89 – 1.91) 
Diuretic 
± BB 
0.18 
(0.02 – 0.91) 
0.21 
(0.02 – 1.44) 
0.34 
(0.08 – 1.03) 
0.35 
(0.09 – 1.04) 
0.35 
(0.09 – 1.05) 
0.36 
(0.09 – 1.06) 
0.37 
(0.09 – 1.08) 
0.38 
(0.09 – 1.15) 
0.29 
(0.07 – 0.89) 
ACEi + 
CCB 
1.20 
(0.44 – 3.24) 
0.34 
(0.08 – 1.09) 
0.34 
(0.08 – 1.09) 
0.34 
(0.08 – 1.1) 
0.35 
(0.08 – 1.12) 
0.36 
(0.09 – 1.14) 
0.38 
(0.09 – 1.21) 
0.28 
(0.07 – 0.94) 
0.98 
(0.67 – 1.46) 
ACEi + 
diuretic 
 514 
 515 
Numbers express the HR for the treatments in the lower line compared to the treatment in the upper line. In total 516 
mortality section, HR < 1 favours the line-defining treatment. In  CV mortality section, HR < 1 favours the row-517 
defining treatment. Results with evidence of benefit are in bold and underlined.  518 
BB = betablocker, CCB = calcium channel blocker, ACEi = angiotensin-converting enzyme inhibitor, ARB = 519 
angiotensin receptor blocker 520 
HR for total mortality (95% CrI) HR for CV mortality (95% CrI) 
25 
 
Table 3: Comparisons of the effects of antihypertensive drug classes in end of study blood pressure 521 
(median difference mmHg (95% CrI).  522 
Placebo -1.07 
(-3.35 to 1.17) 
-1.46 
(-3.59 to 0.71) 
-1.63 
(-3.29 to 0.01) 
-0.84 
(-2.66 to 0.99) 
-1.56 
(-3.09 to -0.04) 
-3.50 
(-5.62 to -1.41) 
-3.38 
(-7.17 to 0.41) 
Thiazide -0.39 
(-2.66 to 1.93) 
-0.56 
(-2.24 to 1.12) 
0.23 
(-1.45 to 1.94) 
-0.49 
(-2.77 to 1.78) 
-2.43 
(-4.66 to -0.21) 
-1.38 
(-5.01 to 2.27) 
1.99 
(-1.84 to 5.89) 
Betablocker -0.16 
(-1.97 to 1.55) 
0.62 
(-1.19 to 2.40) 
-0.10 
(-2.12 to 1.85) 
-2.04 
(-4.34 to 0.19) 
-2.19 
(-5.00 to 0.57) 
1.19 
(-1.63 to 3.96) 
-0.80 
(-3.80 to 2.10) 
CCB 0.79 
(-0.40 to 2.01) 
0.06 
(-1.55 to 1.68) 
-1.87 
(-3.58 to -0.17) 
-1.00 
(-4.08 to 2.03) 
2.37 
(-0.41 to 5.17) 
0.37 
(-2.71 to 3.41) 
1.18 
(-0.78 to 3.16) 
ACEi -0.73 
(-2.59 to 1.10) 
-2.67 
(-4.31 to -1.03) 
-3.34 
(-5.96 to -0.73) 
0.04 
(-3.77 to 3.81) 
-1.95 
(-5.30. to 1.34) 
-1.14 
(-3.85 to 1.56) 
-2.32 
(-5.41 to 0.75) 
ARB -1.93 
(-4.12 to 0.24) 
-4.97 
(-8.60 to -1.50) 
-1.59 
(-5.37 to 2.05) 
-3.59 
(-7.54 to 0.16) 
-2.78 
(-5.73 to 0.02) -3.97 
(-6.77 to -1.27) 
-1.64 
(-5.37 to 1.97) 
ACEi + CCB 
 523 
 524 
Numbers express the difference in end of study blood pressure for the treatment in the lower line related to the 525 
treatment in the upper line. In systolic blood pressure line, median differences < 0 favours line-defining treatment. 526 
In diastolic blood pressure section, median differences < 0 favours row-defining treatment. Results with evidence 527 
of benefit are in bold and underlined.  528 
CCB = calcium channel blocker, ACEi = angiotensin-converting enzyme inhibitor, ARB = angiotensin receptor 529 
blocker 530 
Systolic blood pressure Diastolic blood pressure 
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 531 
Figure 1: Flowchart of study selection process 532 
 533 
Figure 2 Hazard Ratio for total mortality (A) and cardiovascular mortality (B) considering 534 
placebo as reference treatment.  535 
CCB = calcium channel blocker, ACEI = angiotensin converting enzyme inhibitor, ARB = 536 
angiotensin receptor blocker, BB = betablocker 537 
Vertical line represents the no effect line. X-axis represents the Hazard ratio 538 
